Polymerizable composition for optical material, optical material obtained from the composition, and plastic lens
US-2018341043-A1 · Nov 29, 2018 · US
US11066530B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11066530-B2 |
| Application number | US-201916361947-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 22, 2019 |
| Priority date | May 1, 2018 |
| Publication date | Jul 20, 2021 |
| Grant date | Jul 20, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method for preparing an ophthalmic device containing an ultraviolet (UV) blocker is disclosed. The method involves (a) soaking an ophthalmic device in one or more first solvent solutions to swell the ophthalmic device; (b) soaking the swelled ophthalmic device in one or more second solvents solutions comprising a UV blocker to de-swell the ophthalmic device and entrap the UV blocker in the ophthalmic device, wherein the UV blocker is a benzotriazole and (c) sterilizing the de-swelled ophthalmic device.
Opening claim text (preview).
What is claimed is: 1. A method for preparing an ophthalmic device containing an ultraviolet (UV) blocker comprising: (a) soaking an ophthalmic device in one or more first solvent solutions to swell the ophthalmic device; (b) soaking the swelled ophthalmic device in one or more second solvent solutions comprising a UV blocker to de-swell the ophthalmic device and entrap the UV blocker in the ophthalmic device, wherein the UV blocker is a benzotriazole of formula I: wherein each R is independently hydrogen, a halogen, an —O— group, a nitro group, a nitrile group, an alkoxy group, a hydroxyl group, an alkyl group, a cycloalkyl group, an alkynyl group, an alkene group, an aromatic group, an amine group, a carbonyl group, and a heterocyclic group, R* is a linear or branched C 3 to C 28 alkyl, a nitro group, a nitrile group, an alkoxy group, a hydroxyl group, a cycloalkyl group, an alkynyl group, an alkene group, an aromatic group, an amine group, a carbonyl group, and a heterocyclic group, and R** is hydrogen, a linear C 1 to C 8 alkyl group, a branched C 3 to C 8 alkyl, a halogen, a nitro group, a nitrile group, an alkoxy group, a hydroxyl group, a cycloalkyl group, an alkynyl group, an alkene group, an aromatic group, an amine group, a carbonyl group, and a heterocyclic group; and (c) sterilizing the de-swelled ophthalmic device. 2. The method of claim 1 , wherein the one or more first solvent solutions comprise one or more of a low molecular weight alcohol solvent, an aliphatic hydrocarbon solvent, a cycloaliphatic hydrocarbon solvent, a ketone solvent, a nitrile solvent, an ether solvent, and an amido group-containing solvent. 3. The method of claim 2 , wherein the low molecular weight alcohol solvent is a low molecular weight monohydric alcohol having about 1 to about 13 carbon atoms and/or a molecular weight of no greater than about 200. 4. The method of claim 1 , wherein the one or more first solvent solutions comprise a blend of a low molecular weight alcohol solvent and water. 5. The method of claim 1 , wherein the ophthalmic device is soaked in the one or more first solvent solutions for a time period ranging from about 5 minutes to about 120 minutes. 6. The method of claim 1 , wherein step (a) comprises: (i) soaking the ophthalmic device in the one or more first solvent solutions comprising a blend of a low molecular weight alcohol solvent and water for a time period ranging from about 5 minutes to about 120 minutes; and (ii) soaking the ophthalmic device of step (i) in another solvent solution comprising one or more of the same or different low molecular weight alcohol solvent, an aliphatic hydrocarbon solvent, a cycloaliphatic hydrocarbon solvent, a ketone solvent, a nitrile solvent, an ether solvent, and an amido group-containing solvent for a time period ranging from about 5 minutes to about 60 minutes. 7. The method of claim 1 , wherein for the benzotriazole of formula I, each R is hydrogen, R* is a branched C 3 to C 8 alkyl group and R** is a branched C 3 to C 8 alkyl group. 8. The method of claim 1 , wherein for the benzotriazole of formula I, each R is hydrogen, R* is a linear C 8 to C 28 alkyl group and R** is a linear C 1 to C 8 alkyl group. 9. The method of claim 1 , wherein for the benzotriazole of formula I, each R is hydrogen, R* is a linear C 10 to C 28 alkyl group and R** is a linear C 1 to C 8 alkyl group. 10. The method of claim 1 , wherein the benzotriazole of formula I is a benzotriazole of formula II: wherein R, R* and R** have the aforestated meanings. 11. The method of claim 1 , wherein the benzotriazole of general formula I is selected from the group consisting of 2-(2H-benzotriazole-2-yl)-6-dodecyl-4-methylphenol and 2-(2H-benzotriazole-2-yl)-4,6-ditert-pentylphenol. 12. The method of claim 1 , wherein the one or more second solvent solutions comprise one or more of water, a low molecular weight alcohol solvent, an aliphatic hydrocarbon solvent, a cycloaliphatic hydrocarbon solvent, a ketone solvent, a nitrile solvent, an ether solvent, and an amido group-containing solvent. 13. The method of claim 12 , wherein the low molecular weight alcohol solvent is a low molecular weight monohydric alcohol having about 1 to about 13 carbon atoms and/or a molecular weight of no greater than about 200. 14. The method of claim 1 , wherein the one or more second solvent solutions comprise a blend of a low molecular weight alcohol solvent and water. 15. The method of claim 1 , wherein the UV blocker is present in the one or more second solvent solutions in an amount ranging from about 0.05 to about 3 wt. %, based on the total weight of the second solvent solution. 16. The method of claim 1 , wherein the ophthalmic device is soaked in the one or more second solvent solutions for a time period ranging from about 5 minutes to about 120 minutes. 17. The method of claim 1 , wherein step (b) comprises: (i) soaking the swelled ophthalmic device in the one or more second solvent solutions comprising a low molecular weight alcohol solvent and the UV blocker for a time period ranging from about 5 minutes to about 20 minutes; and (ii) soaking the ophthalmic device of step (i) in another solvent solution comprising a blend of the same or different low molecular weight alcohol solvent of the one or more second solvent solutions and water and the UV blocker for a time period ranging from about 5 minutes to about 20 minutes. 18. The method of claim 1 , further comprising soaking the de-swelled ophthalmic device in one or more third solvent solutions comprising water prior to step (c). 19. The method of claim 1 , wherein step (c) comprises autoclaving the ophthalmic device. 20. The method of claim 19 , further comprising the step of applying a lid stock to a package containing the ophthalmic device prior to subjecting the ophthalmic device to a step of autoclaving. 21. The method of claim 1 , further comprising incorporating a photochromic material into the ophthalmic device. 22. The method of claim 21 , wherein the photochromic material is a blue blocker. 23. The method of claim 1 , wherein the ophthalmic device is one or more of a contact lens, an intraocular lens and a corneal implant. 24. The method of claim 23 , wherein the contact lens is a soft contact lens. 25. The method of claim 23 , wherein the contact lens is a hydrogel contact lens. 26. The method of claim 23 , wherein the contact lens is a silicone hydrogel contact lens. 27. The method of claim 23 , wherein the contact lens is a rigid gas permeable contact lens. 28. An ophthalmic device comprising a UV blocker entrapped in a polymerization product of a monomeric mixture comprising one or more ophthalmic device-forming monomers, wherein the UV blocker is a benzotriazole of formula I: wherein each R is independently hydrogen, a halogen, an —O— group, a nitro group, a nitrile group, an alkoxy group, a hydroxyl group, an alkyl group, a cycloalkyl group, an alkynyl group, an alkene group, an aromatic group, an amine group, a carbonyl group, and a heterocyc
Implants for natural eyes · CPC title
Polysiloxanes · CPC title
Hydrogen peroxide; Peroxy compounds · CPC title
Production of contact lenses · CPC title
Contact lenses for the eyes (disinfection or sterilisation of contact lenses A61L12/00) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.